Top 10 Assisted Reproductive Technology Companies

Why Assisted Reproductive Technology Market Are Expanding?

The Assisted Reproductive Technology (ART) Market is undergoing sustained structural growth, rising from USD 27.51 billion in 2024 to a projected USD 45.02 billion by 2035, registering a CAGR of 4.5% during the 2025–2035 forecast period. Market Research Future (MRFR) identifies three converging macro forces driving this expansion: a global infertility epidemic now affecting 1 in 6 adults as quantified by WHO, a demographic shift toward delayed parenthood with average first-birth age exceeding 30 in over 40 countries, and rapid adoption of genetic-screening and embryo-selection technologies that are materially improving IVF success rates.

North America accounts for a revenue share of 45.07% in the market and is expected to hit around USD 12.4 billion in 2024. It is due to strong employer-sponsored fertility benefit coverage offered by over 60% of the Fortune 500 organizations.

The procedure-type section of IVF is the leading segment, contributing 68% of the revenue, owing to continuous protocol advancements and increasing insurance reimbursement mandates. ICSI is the fastest growing technique with a 32% share and accelerated growth rate, driven by increasing diagnoses of male infertility and proliferation of microfluidic sperm-selection equipment.

Fertility clinics account for 72% of end-user revenue share, while hospital-based ART programs are growing at a faster absolute pace as integrated health systems create dedicated reproductive medicine units to capitalize on the fertility benefit boom. Preimplantation genetic diagnosis (PGD) and cryopreservation are the fastest-growing technological divisions, according to next-generation sequencing and vitrification developments that limit cryopreservation-related embryo damage to less than 1%.

Why Are These Companies Leading the Market?

MRFR identifies four structural factors separating category leaders in the Assisted Reproductive Technology Market: integrated workflow coverage, technology differentiation through AI and genetic testing, global clinic or distribution network reach, and disciplined M&A strategy that closes capability gaps. Companies with the largest revenue positions are combining unique consumables or pharmacological portfolios with data-driven embryo-selection platforms, allowing them to serve the whole ART cycle from stimulation to live birth.

CooperSurgical, Inc. integrated workflow coverage spanning diagnostics, gamete media, sperm-selection devices and genetic testing in a single commercial ART service distributed throughout 130+ countries. An example of technology differentiation is Vitrolife AB, which with its EmbryoScope time-lapse incubator and AutoIVF AI investment, enables non-invasive embryo assessment, avoiding invasive biopsy in morphokinetic selection processes.

IVIRMA Global has an unmatched geographic clinic network reach, with 75 fertility clinics in 15 countries and the leading aggregate IVF treatment volume worldwide. M&A strategy fuels Hamilton Thorne’s competitive expansion The company combined with Cook Medical’s IVF division for USD 282 million Astorg-led deal to build integrated platform for ART equipment and consumables.

Top 10 Global Assisted Reproductive Technology Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading assisted reproductive technology companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

*Rankings based on MRFR analysis. Revenue figures sourced from official company filings, investor relations disclosures, and analyst estimates. CAGR reflects company-guided or analyst-estimated growth for ART-relevant segments.

Detailed Company Profiles

CooperSurgical, Inc. | NASDAQ: COO (via CooperCompanies) | Trumbull, Connecticut, USA

CooperSurgical, Inc. is the ART market's most comprehensive workflow integrator, delivering IVF culture media, sperm-selection devices, genetic testing via CooperGenomics, gamete cryopreservation services, and embryo transfer catheters within a unified commercial portfolio deployed across 130+ countries.

The company's fertility segment encompasses consumables, capital equipment, and genetic testing, with a strategic focus on embedding preimplantation genetic testing for aneuploidy (PGT-A) into standard IVF protocols to improve euploid blastocyst selection accuracy. CooperSurgical serves over 600 IVF clinics globally through its SAGE and Wallace branded laboratory consumables lines, and manages donor sperm inventories through its California Cryobank network.

IVIRMA Global | Private (KKR, Abu Dhabi Capital Group) | Valencia, Spain

IVIRMA Global is the world's largest assisted reproduction group by clinic volume, combining the IVI (Instituto Valenciano de Infertilidad) European network with the RMA (Reproductive Medicine Associates) North American clinic system into a 75-clinic platform spanning 15 countries across Europe, North America, and the Middle East.

The group's clinical model integrates in-house research — with over 400 peer-reviewed publications annually — with standardized ART protocols, donor egg programs, surrogacy coordination, and genetic counseling across all clinic locations. IVIRMA has established a particularly strong position in Spain and the US East Coast, where its RMA network serves complex-case referrals and egg donation recipients from across the Americas.

Vitrolife AB | Nasdaq Stockholm: VITR | Gothenburg, Sweden

Vitrolife AB is the global leader in IVF culture media and time-lapse embryo incubation, delivering its EmbryoScope portfolio, G-Series culture media, and cryopreservation solutions to over 2,200 IVF clinics across 35+ countries. The company's EmbryoScope+ time-lapse incubator captures continuous embryo images throughout culture, enabling morphokinetic embryo assessment without dish removal and reducing embryo exposure to ambient conditions during selection.

Vitrolife's acquisition of Igenomix in 2021 added genetic testing to its portfolio, providing the company with an end-to-end embryo-lab capability spanning culture through chromosomal analysis.

Progyny, Inc. | NASDAQ: PGNY | New York, New York, USA

Progyny, Inc. is the leading employer-sponsored fertility benefit manager in the United States, providing evidence-based fertility and family-building benefit programs to Fortune 500 and mid-market employers covering over 5 million lives through a network of 900+ fertility specialists across 40+ states.

The company's Smart Cycle benefit design bundles fertility consultations, IVF procedures, genetic testing, and medication management into pre-approved treatment units, eliminating prior authorization delays and improving clinical outcome accountability. Progyny's pharmacy benefit services additionally dispense specialty fertility medications through partnerships with specialty pharmacies, capturing pharmaceutical margin alongside clinical benefit administration.

Merck KGaA (EMD Serono) | XETRA: MRK | Darmstadt, Germany

Merck KGaA's Healthcare sector is called EMD Serono in North America. The company is the world's top supplier of pharmaceuticals for fertility hormone therapy. Its product Gonal-f (follitropin alfa) is the leading product in the recombinant FSH market for in vitro fertilization (IVF) ovarian stimulation protocols in more than 66 countries.

The company’s fertility portfolio also includes Ovidrel (choriogonadotropin alfa) for ovulation triggering, Cetrotide (cetrorelix) for prevention of premature LH surge and Elonva (corifollitropin alfa) for once weekly stimulation, providing a complete pharmacological toolkit for ART treatment cycles. Merck KGaA’s reproductive division invests in digital medication management platforms that link treating physicians with adherence tracking and injectable training aids for IVF patients.

Ferring Pharmaceuticals | Private | Saint-Prex, Switzerland

Ferring Pharmaceuticals is a research-driven biopharmaceutical company with a primary strategic focus on reproductive medicine, maintaining one of the broadest fertility pharmacotherapy portfolios among dedicated pharmaceutical companies, including Rekovelle (follitropin delta), Menopur (menotropins), Bravelle (urofollitropin), and Endometrin (progesterone).

Rekovelle's differentiated dosing algorithm, based on the CONSORT trial personalizing FSH dose by AMH level and body weight, positions it as the most clinically advanced gonadotropin in current commercial deployment. Ferring operates manufacturing and distribution across 100+ countries with particular depth in Europe, North America, and growing presence in Asia-Pacific fertility pharmacotherapy markets.

Hamilton Thorne Ltd. | Private (was TSXV: HTL) | Beverly, Massachusetts, USA

Hamilton Thorne Ltd. is a specialist ART capital equipment and imaging technology company, delivering LYKOS laser systems for assisted hatching and embryo biopsy, CASA (Computer-Assisted Sperm Analysis) systems for male fertility diagnostics, AI-powered embryo morphology imaging, and — following its merger with Cook Medical's IVF division — an expanded consumables portfolio covering embryo transfer catheters, biopsy pipettes, and laboratory plasticware.

The company's integrated hardware-software approach positions it as a full embryology laboratory infrastructure provider for single-site and multi-clinic ART networks. Hamilton Thorne's platforms are deployed in over 1,000 IVF laboratories across 45+ countries.

Genea Limited (Genea Biomedx) | Private | Sydney, Australia

Genea Limited operates two divisions: Genea Fertility (clinic services across 25+ Australian and international locations) and Genea Biomedx (global ART technology commercialization), with the Biomedx division serving as the primary international revenue driver through its Geri time-lapse incubator, GIVF embryo culture media, and preimplantation genetic testing services.

The Geri incubator's multi-well design enables 16 patients' embryos to be cultured simultaneously in individually controlled micro-environments, reducing embryo handling and providing continuous morphokinetic data. Genea's technology platform is used in over 600 IVF clinics globally across 25+ countries, with particular density in Europe, the UK, and Australasia.

FUJIFILM Irvine Scientific | Part of FUJIFILM Holdings (TYO: 4901) | Santa Ana, California, USA

FUJIFILM Irvine Scientific is one of the world’s largest makers of ART culture medium, cryoprotectants and gamete handling products, with its IVF products, Global Total Medium and Quinn’s Advantage Medium brands used in IVF facilities in 50+ countries. The company’s product line includes fertilization media, embryo culture media, cryopreservation media and sperm processing reagents, offering total consumable coverage of the IVF laboratory workflow.

Fujifilm. Irvine Scientific’s state-of-the-art production facilities are situated in Santa Ana, California and Tilburg, Netherlands and are certified to ISO 13485 and fully compliant with EU IVD requirements.

Monash IVF Group | ASX: MVF | Melbourne, Australia

Monash IVF Group is Australia's leading integrated fertility clinic operator, tracing its heritage to Monash University's 1973 pioneering IVF research that produced Australia's first IVF baby in 1980. The group operates 30+ fertility clinics across Australia and Southeast Asia (Malaysia and Indonesia), providing IVF, ICSI, frozen embryo transfer, egg freezing, preimplantation genetic testing, sperm donation, and male fertility diagnostic services.

Monash IVF's clinical research heritage and academic partnerships with Monash University's Hudson Institute of Medical Research maintain its position as a scientific reference point for ART practice in the Asia-Pacific region.

M&A Activity Tracker (2022–2026)

The Assisted Reproductive Technology Market has experienced accelerating consolidation as private equity investors, fertility clinic networks, and ART technology companies pursue inorganic growth strategies to expand geographic footprint, acquire proprietary technology platforms, and achieve operational scale in a market where clinical volume and data density are primary competitive advantages. Market Research Future tracks the following verified transactions directly relevant to the ART market:

Key Trend: MRFR analysis identifies private equity-driven clinic network consolidation and technology capability acquisition as the dominant M&A themes in the ART market, with acquirers prioritizing AI-enabled embryo selection platforms and multi-geography fertility clinic networks that generate recurring procedure revenue and proprietary outcome data assets.

R&D Investment & Innovation Signals

The Assisted Reproductive Technology Market has experienced significant growth in R&D investment in 2025–2026, as ART companies are competing to incorporate AI-enabled embryo selection, non-invasive genetic testing and precision pharmacotherapy personalization to clinical processes, to overcome the major challenges of IVF success rate inconsistency and high treatment cost. Market Research Future has tracked the following certified 2025-2026 R&D and technology plans from the company’s official website:

• CooperSurgical, Inc. develops CooperGenomics, an AI-driven embryo selection technology that combines preimplantation genetic testing (PGT-A) with morphokinetic time-lapse data to improve blastocyst euploid selection accuracy in IVF cycles worldwide.
• Vitrolife AB invested in AutoIVF in May 2025, to integrate deep learning embryo assessment algorithms directly into the EmbryoScope time-lapse incubator workflow, providing automated morphokinetic grading without the need for manual embryologist scoring.
• IVIRMA Global runs the world’s biggest ART clinical research network with 75 clinics, publishing over 400 peer-reviewed reproductive endocrinology studies in 2024-2025 and conducting multi-center RCTs on embryo selection and ovarian stimulation protocols.
• Progyny, Inc. unveiled improved fertility benefit analytics in 2025, employing machine learning on over 1 million covered member cycles to uncover therapeutic procedures linked to greater live-birth rates, and shared those insights with its 400+ network clinic partners.
• Merck KGaA (EMD Serono) invests in next-generation gonadotropin formulations and delivery systems of recombinant FSH, developing the Gonal-f biosimilar portfolio and evaluating new long-acting follicle stimulating hormone compounds in Phase II trials.
• Hamilton Thorne Ltd. expanded its LYKOS laser and AI-based sperm analysis platform in 2025 to include post-Cook Medical IVF hardware and cloud-based embryology data management to benchmark cross-clinic outcomes.
• Genea Biomedx and AIVF jointly create AI-based IVF result prediction models to enable embryo-transfer decision tools that incorporate morphokinetics, patient history and stimulation protocol data in the Geri time-lapse incubator environment.
• FUJIFILM Irvine Scientific is focusing R&D resources on enhanced ART culture media optimization with the development of low-oxygen and single-step sequential media formulations aimed at improving blastocyst development rates in high-throughput IVF laboratories.

Industry Signal: MRFR recognizes the convergence of non-invasive preimplantation genetic testing with AI morphokinetic embryo scoring as the overall innovation direction that is reshaping competitive differentiation in the ART market. Vendors that succeed in delivering validated non-biopsy euploid selection will be positioned to redefine the standard of care and command premium pricing in high-volume IVF clinic partnerships.